Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867594 | 1.00 | KMT2A (0.59) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL4080893 | 1.00 | KMT2A (0.59) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL15850937 | 0.87 | KMT2A (0.61) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL13752131 | 0.87 | KMT2A (0.61) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL13495538 | 0.87 | KMT2A (0.61) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL3123853 | 0.86 | KMT2A (0.58) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL3123858 | 0.86 | KMT2A (0.58) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL3114229 | 0.86 | KMT2A (0.54) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL3120822 | 0.86 | KMT2A (0.54) | KMT2AMAPK1GRM5P2RX3CYP2D6 | |
| SCHEMBL8312108 | 0.86 | KMT2A (0.54) | KMT2AMAPK1GRM5P2RX3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7381747-B2 | Alpha 2 delta ligands for post-traumatic stress disorder | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-03 | — | — | US | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | KMT2A 1327/4885MAPK1 519/4885GRM5 189/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | KMT2A 1829/4885MAPK1 917/4885GRM5 112/4885 |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | KMT2A 1327/4885MAPK1 519/4885GRM5 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.